|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Strom C: Breast cancer: Diagnostic service
shares BRCA data. Nature. 522:342015. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou M, Zhong L, Xu W, Sun Y, Zhang Z,
Zhao H, Yang L and Sun J: Discovery of potential prognostic long
non-coding RNA biomarkers for predicting the risk of tumor
recurrence of breast cancer patients. Sci Rep. 6:310382016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yin Y, Cai J, Meng F, Sui C and Jiang Y:
miR-144 suppresses proliferation, invasion, and migration of breast
cancer cells through inhibiting CEP55. Cancer Biol Ther.
19:306–315. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hwang MS, Yu N, Stinson SY, Yue P, Newman
RJ, Allan BB and Dornan D: miR-221/222 targets adiponectin receptor
1 to promote the epithelial-to-mesenchymal transition in breast
cancer. PLoS One. 8:e665022013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang X and Meng T: MicroRNA-431 affects
trophoblast migration and invasion by targeting ZEB1 in
preeclampsia. Gene. 683:225–232. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kwok GTY, Zhao JT, Glover AR, Gill AJ,
Clifton-Bligh R, Robinson BG, Ip JCY and Sidhu SB: microRNA-431 as
a chemosensitizer and potentiator of drug activity in
adrenocortical carcinoma. Oncologist. 24:e241–e250. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee KP, Shin YJ, Panda AC, Abdelmohsen K,
Kim JY, Lee SM, Bahn YJ, Choi JY, Kwon ES, Baek SJ, et al: miR-431
promotes differentiation and regeneration of old skeletal muscle by
targeting Smad4. Genes Dev. 29:1605–1617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Li L, Liu Z, Yuan Q and Lu X:
Downregulation of miR-431 expression associated with lymph node
metastasis and promotes cell invasion in papillary thyroid
carcinoma. Cancer Biomark. 22:727–732. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang J, Zhu H, Jin Y and Song Y: miR-431
inhibits cell proliferation and induces cell apoptosis by targeting
CDK14 in pancreatic cancer. Eur Rev Med Pharmacol Sci.
22:4493–4499. 2018.PubMed/NCBI
|
|
12
|
Su N, Jin M and Chen L: Role of FGF/FGFR
signaling in skeletal development and homeostasis: Learning from
mouse models. Bone Res. 2:140032014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohgino K, Soejima K, Yasuda H, Hayashi Y,
Hamamoto J, Naoki K, Arai D, Ishioka K, Sato T, Terai H, et al:
Expression of fibroblast growth factor 9 is associated with poor
prognosis in patients with resected non-small cell lung cancer.
Lung Cancer. 83:90–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang S, Lin H, Zhao T, Huang S, Fernig DG,
Xu N, Wu F, Zhou M, Jiang C and Tian H: Expression and purification
of an FGF9 fusion protein in E. coli, and the effects of the
FGF9 subfamily on human hepatocellular carcinoma cell proliferation
and migration. Appl Microbiol Biotechnol. 101:7823–7835. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li K, Pan J, Wang J, Liu F and Wang L:
miR-665 regulates VSMCs proliferation via targeting FGF9 and MEF2D
and modulating activities of Wnt/β-catenin signaling. Am J Transl
Res. 9:4402–4414. 2017.PubMed/NCBI
|
|
16
|
Yang H, Fang F, Chang R and Yang L:
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting
transforming growth factor β receptor 1 and fibroblast growth
factor 9 in hepatocellular carcinoma. Hepatology. 58:205–217. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li W, Yi J, Zheng X, Liu S, Fu W, Ren L,
Li L, Hoon DSB, Wang J and Du G: miR-29c plays a suppressive role
in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clin
Epigenetics. 10:642018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang J, He Y, Yu Y, Chen X, Cui G, Wang
W, Zhang X, Luo Y, Li J, Ren F, et al: Upregulation of miR-374a
promotes tumor metastasis and progression by downregulating LACTB
and predicts unfavorable prognosis in breast cancer. Cancer Med.
7:3351–3362. 2018. View Article : Google Scholar
|
|
19
|
Jiang Q, Cheng L, Ma D and Zhao Y:
FBXL19-AS1 exerts oncogenic function by sponging miR-431-5p to
regulate RAF1 expression in lung cancer. Biosci Rep. 39:392019.
View Article : Google Scholar
|
|
20
|
Li MF, Li YH, He YH, Wang Q, Zhang Y, Li
XF, Meng XM, Huang C and Li J: Emerging roles of hsa_circ_0005075
targeting miR-431 in the progress of HCC. Biomed Pharmacother.
99:848–858. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pan L, Ren F, Rong M, Dang Y, Luo Y, Luo D
and Chen G: Correlation between down-expression of miR-431 and
clinicopathological significance in HCC tissues. Clin Transl Oncol.
17:557–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun K, Zeng T, Huang D, Liu Z, Huang S,
Liu J and Qu Z: MicroRNA-431 inhibits migration and invasion of
hepatocellular carcinoma cells by targeting the ZEB1-mediated
epithelial-mensenchymal transition. FEBS Open Bio. 5:900–907. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu CM, Chen LX, Gao F, Zhu MF, Dai Y, Xu Y
and Qian WX: miR-431 suppresses proliferation and metastasis of
lung cancer via down-regulating DDX5. Eur Rev Med Pharmacol Sci.
23:699–707. 2019.PubMed/NCBI
|
|
24
|
Wu YZ, Chan KYY, Leung KT, Lam HS, Tam YH,
Lee KH, Li K and Ng PC: Dysregulation of miR-431 and target gene
FOXA1 in intestinal tissues of infants with necrotizing
enterocolitis. FASEB J. 33:5143–5152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kong Q, Han J, Deng H, Wu F, Guo S and Ye
Z: miR-431-5p alters the epithelial-to-mesenchymal transition
markers by targeting UROC28 in hepatoma cells. OncoTargets Ther.
11:6489–6503. 2018. View Article : Google Scholar
|
|
26
|
Yu B, Qian T, Wang Y, Zhou S, Ding G, Ding
F and Gu X: miR-182 inhibits Schwann cell proliferation and
migration by targeting FGF9 and NTM, respectively at an early stage
following sciatic nerve injury. Nucleic Acids Res. 40:10356–10365.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rao C, Miao X, Zhao G, Zhang C, Shen H,
Dong C and Yang M: miR-219a-5p enhances cisplatin sensitivity of
human non-small cell lung cancer by targeting FGF9. Biomed
Pharmacother. 114:1086622019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu
YX, Liu JF and He ZM: miR-26a suppresses tumor growth and
metastasis by targeting FGF9 in gastric cancer. PLoS One.
8:e726622013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang H, Luo R, Chen X, Zhao Y and Tan A:
miR-187 inhibits the growth of cervical cancer cells by targeting
FGF9. Oncol Rep. 38:1977–1984. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang R, Sun Y, Yu W, Yan Y, Qiao M, Jiang
R, Guan W and Wang L: Downregulation of miRNA-214 in
cancer-associated fibroblasts contributes to migration and invasion
of gastric cancer cells through targeting FGF9 and inducing EMT. J
Exp Clin Cancer Res. 38:202019. View Article : Google Scholar : PubMed/NCBI
|
